Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Yuze Wu(Tongji Hospital), Kongming Wu(First Affiliated Hospital of Zhengzhou University)
Cited by 458
Related Papers
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
|Molecular Cancer|2022|1.4k
Chimeric antigen receptor T cells: a novel therapy for solid tumors
|Journal of Hematology & Oncology|2017|306
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
|Molecular Cancer|2019|266
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
|Journal of Hematology & Oncology|2022|178
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
|Journal of Hematology & Oncology|2021|176